Study With Heparin Sodium in Intravenous Administration
NCT03125187 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2019-10-15
Summary
The purpose of this phase I study is to know the pharmacodynamic profile in in intravenous application in humans of the sodium heparin of porcine origin of the company União Química, building from the pharmacodynamic data generated its pharmacokinetic profile, due to the dosage limitation of heparin directly in biological samples. In addition, the toxicity of the product will be evaluated in healthy male participants.
Conditions
- Heparin
Interventions
- BIOLOGICAL
-
Sodium heparin UQ Intravenous drug administration
The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
- BIOLOGICAL
-
Sodium heparin FK Intravenous drug administration
The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Sponsors & Collaborators
-
Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME
collaborator INDUSTRY -
União Química Farmacêutica Nacional S/A
lead INDUSTRY
Principal Investigators
-
Paula F Santos · União Química Farmacêutica Nacional S/A
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-02-20
- Primary Completion
- 2021-02-20
- Completion
- 2022-11-10
- FDA Drug
- Yes
Countries
- Brazil
Study Locations
More Related Trials
-
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment
NCT05225155 ·Status: COMPLETED
-
Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.
NCT04561648 ·Status: RECRUITING ·Phase: NA
-
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
NCT03064035 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
NCT03426982 ·Status: UNKNOWN ·Phase: PHASE4
-
Study on Antithrombotic Prevention in Thrombophilia and Pregnancy Loss
NCT02385461 ·Status: UNKNOWN
-
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
NCT00934167 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
NCT02206087 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function
NCT00264693 ·Status: COMPLETED
-
Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography
NCT01260519 ·Status: COMPLETED ·Phase: PHASE3
-
High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion
NCT02570243 ·Status: COMPLETED ·Phase: PHASE4
-
Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
NCT00277394 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
NCT03140631 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration
NCT01692171 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose
NCT01692158 ·Status: COMPLETED ·Phase: PHASE1
-
Administration of Fibrinogen Concentrate for Refractory Bleeding
NCT05091684 ·Status: TERMINATED ·Phase: PHASE2
-
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
NCT01531829 ·Status: UNKNOWN ·Phase: PHASE4
-
A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
NCT01759394 ·Status: COMPLETED ·Phase: PHASE1
-
Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed
NCT02565836 ·Status: COMPLETED
-
Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins
NCT00055159 ·Status: COMPLETED ·Phase: PHASE1
-
Reversal of the Antithrombotic Action of New Oral Anticoagulants
NCT01478282 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
NCT00311753 ·Status: COMPLETED ·Phase: PHASE3
-
Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
NCT00927602 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
NCT00851864 ·Status: COMPLETED ·Phase: PHASE4